JP2023011857A5 - - Google Patents

Download PDF

Info

Publication number
JP2023011857A5
JP2023011857A5 JP2022177061A JP2022177061A JP2023011857A5 JP 2023011857 A5 JP2023011857 A5 JP 2023011857A5 JP 2022177061 A JP2022177061 A JP 2022177061A JP 2022177061 A JP2022177061 A JP 2022177061A JP 2023011857 A5 JP2023011857 A5 JP 2023011857A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
fusion protein
chemotherapeutic agents
antimicrobial agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022177061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023011857A (ja
JP7532475B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2017/021715 external-priority patent/WO2017156356A1/en
Application filed filed Critical
Publication of JP2023011857A publication Critical patent/JP2023011857A/ja
Publication of JP2023011857A5 publication Critical patent/JP2023011857A5/ja
Application granted granted Critical
Publication of JP7532475B2 publication Critical patent/JP7532475B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022177061A 2016-03-10 2022-11-04 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 Active JP7532475B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662306281P 2016-03-10 2016-03-10
US62/306,281 2016-03-10
PCT/US2017/021715 WO2017156356A1 (en) 2016-03-10 2017-03-10 Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
JP2018547409A JP2019512233A (ja) 2016-03-10 2017-03-10 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018547409A Division JP2019512233A (ja) 2016-03-10 2017-03-10 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法

Publications (3)

Publication Number Publication Date
JP2023011857A JP2023011857A (ja) 2023-01-24
JP2023011857A5 true JP2023011857A5 (https=) 2023-06-15
JP7532475B2 JP7532475B2 (ja) 2024-08-13

Family

ID=59789900

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018547409A Pending JP2019512233A (ja) 2016-03-10 2017-03-10 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法
JP2022177061A Active JP7532475B2 (ja) 2016-03-10 2022-11-04 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018547409A Pending JP2019512233A (ja) 2016-03-10 2017-03-10 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法

Country Status (12)

Country Link
US (1) US10988512B2 (https=)
EP (1) EP3426785A4 (https=)
JP (2) JP2019512233A (https=)
KR (1) KR102430891B1 (https=)
CN (2) CN118599011A (https=)
AU (1) AU2017230792B2 (https=)
BR (1) BR112018068055A2 (https=)
CA (1) CA3017143A1 (https=)
IL (2) IL261660A (https=)
MX (1) MX2018010850A (https=)
WO (2) WO2017156356A1 (https=)
ZA (1) ZA201806450B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3762401A4 (en) * 2018-03-06 2021-12-08 The Johns Hopkins University CANCER TREATMENT OR PREVENTION METHODS USING TREG DEPLETING AGENT AND CHECKPOINT INHIBITOR
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
MX2022000052A (es) * 2019-07-01 2022-04-06 Eisai R&D Man Co Ltd Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766.
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
KR20230102682A (ko) * 2021-12-30 2023-07-07 (주)셀트리온 목적 단백질의 발현 방법
CN114903896B (zh) * 2022-05-30 2023-07-25 广西大学 贝达喹啉在制备治疗弓形虫病药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549855B1 (fr) * 1983-07-29 1987-03-27 Grp Genie Genetique Sequence nucleotidique codant pour le peptide signal de la toxine diphterique, vecteur contenant cette sequence nucleotidique, leur application a la transformation de micro-organismes et compositions peptidiques obtenues
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
CA1340494C (en) * 1988-05-19 1999-04-13 The Beth Israel Hospital Association And Brigham And Women's Hospital Induction of tolerance to a foreign antigen
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
WO1991013090A1 (en) 1990-03-02 1991-09-05 Diane Williams Improved chimeric toxins
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
NO175188C (no) * 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DK0590060T3 (da) 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5654273A (en) 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2004007663A2 (en) 2002-05-22 2004-01-22 Advanced Microbial Solutions Corporation Gene expression using metal ion dependent repressor/operator tandems
EP1687016A4 (en) * 2003-11-25 2009-07-29 Anjin Corp GENETIC VARIANT OF DIPHTHERIC TOXIN
AU2006260240B2 (en) * 2005-06-21 2012-03-15 The Research Foundation For Microbial Diseases Of Osaka University Therapeutic agent for cancer
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
EP2600843B9 (en) * 2010-07-19 2020-03-11 Pressure BioSciences, Inc. Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
WO2012039954A2 (en) * 2010-09-08 2012-03-29 The Scripps Research Institute Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns
WO2012110596A1 (en) * 2011-02-16 2012-08-23 Friedrich-Alexander-Universität Erlangen-Nürnberg Fusion protein for the treatment of immunologic or allergic reactions
KR101895768B1 (ko) * 2011-06-01 2018-09-07 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
US8906681B2 (en) * 2011-08-02 2014-12-09 The Scripps Research Institute Reliable stabilization of N-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns

Similar Documents

Publication Publication Date Title
JP2023011857A5 (https=)
De Clercq Mozobil®(Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
RU2011108026A (ru) Комбинированная терапия туберкулеза
JP2012502017A5 (https=)
Muller et al. Nifedipine and conventional therapy for unstable angina pectoris: a randomized, double-blind comparison.
JP2010523587A5 (https=)
JP2020514317A5 (https=)
KR20150096794A (ko) 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
JP2019031567A5 (https=)
JP2024503265A5 (https=)
JP2021502980A5 (https=)
JP2006501147A5 (https=)
JPWO2019156137A5 (https=)
JP2014508748A5 (https=)
JP2020511542A5 (https=)
JP2016537380A5 (https=)
FI4121058T3 (fi) Oksatsolidinoniyhdiste ja sen käyttö antibakteerisena aineena
JP2019533715A5 (https=)
JP2023546536A5 (https=)
RU2015125300A (ru) Производные фенотиазина и их применение против туберкулеза
JP2022116304A (ja) 血液がんの治療のためのPPARγアゴニスト
JP2025502095A5 (https=)
CN114452403A8 (zh) 一种含有双功能免疫检查点/TGFβ抑制剂的药物组合
JP2006519791A (ja) 新規なnphインスリン製剤
JP2020534266A5 (https=)